Skip to content
ES
MARKETS / NASDAQ / IBRX
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

ImmunityBio, Inc. IBRX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$113.3M
▲ 668.3% YoY
$-351.4M
$-308.8M
In brief

What this company does

Its lead biologic product, ANKTIVA, a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein, is being commercialized for the treatment of BCG-unresponsive NMIBC CIS with or without papillary tumors. It has established NK cell therapy manufacturing facilities at multiple California sites that support its oncology programs. As of December 31, 2025, ImmunityBio employed 691 employees, of which 41% were focused on research and development, 25% on manufacturing and quality, and 34% on selling, general and administrative functions. The majority of its employees are located in its Southern California facilities, with others in its facilities in Washington, Colorado, New Jersey, and New York. The company operates in one operating and one reportable segment. ImmunityBio, Inc. is incorporated in Delaware and its principal executive offices are located in San Diego, California.

Written from the business description in ImmunityBio, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth
USD 113.3M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 113.3 · Net income -351.4
40M80M-200M-400M2013201520172019202120232025
Compound annual growth
+678.6%
+184.8%
+85.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +184.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−310 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -226.0% · Net -310.2%
-100000%-200000%2013201520172019202120232025
ROE
FY2020 · ROE -50941.7%
-20000%-40000%2013201520172019202120232025
Gross margin99.3%
Operating margin-226.0%
Net margin-310.2%
Return on assets-79.4%
EBITDAUSD -240.5M

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -308.8
-200M-400M2013201520172019202120232025
Net buybacks $M Dividends $M
FY2021 · Dividends — · Net buybacks -5.5
5M10M-40M-80M20142015201620172018201920202021
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 501.9M
EquityUSD -500.5M
CashUSD 88.3M
Gross debtUSD 1.8M
Net debtUSD -86.6M
Current ratio5.10×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.10.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.3−0.3−0.4−0.4−0.3−0.2−0.2−0.1−0.1−0.1−0.2−0.0·
EBITDA $B−0.2−0.3−0.3−0.3−0.3−0.2−0.1−0.1−0.1−0.1−0.2−0.0·
Income tax $B−0.00.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0
Net income $B−0.4−0.4−0.6−0.4−0.3−0.2−0.2−0.1−0.1−0.1−0.2−0.0−0.0
Free cash flow $B−0.3−0.4−0.4−0.4−0.3−0.2−0.2−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−0.38−0.62−1.15−1.04−0.89−0.59−0.43−1.22−1.20−1.47−3.31−0.75−2.57
Dividend / sh $·············
Payout %·············
ROE %·····−50941.7−118.3−52.7−37.6−37.2−114.5−23.0·
Shares out B1.010.850.670.420.400.380.100.080.080.080.08··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 43 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image